Pressure BioSciences, Inc.
PBIO · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 20.8% | 11.8% | -24.4% | – |
| Cost of Goods Sold | -$0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 10.5% | 33.2% | -6.8% | -55.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -457.2% | -425.1% | -1,117.7% | -413% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,687.2% | -2,311.9% | -3,170.7% | -1,516.2% |
| EPS | -0.15 | -0.22 | -0.44 | -0.288 |
| % Growth | 31.8% | 50% | -52.6% | – |
| EPS Diluted | -0.15 | -0.22 | -0.44 | -0.288 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -827.9% | -748.3% | -1,108.7% | -305.8% |